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We are exploring analogs of the macrocyclic tetrapeptide natural product CJ-15,208 
(cyclo[Phe-D-Pro-Phe-Trp]) as both potential analgesics and kappa opioid receptor (KOPr) 
antagonists. KOPr agonists exhibit analgesic activity but do not cause some of the adverse side 
effects associated with mu opioid agonists. Additionally, both KOPr agonists and antagonists have 
demonstrated the ability to block reinstatement of cocaine-seeking behavior under different 
conditions. CJ-15,208 has shown both opioid agonist (antinociceptive) activity and KOPr 
antagonist activity in vivo, while its D-Trp isomer, [D-Trp]CJ-15,208, has shown predominantly 
KOPr antagonist activity in vivo. Both compounds penetrate the central nervous system following 
oral administration and are stable to proteases in plasma and whole blood. However, studies in 
liver microsomes suggest that these peptides are susceptible to CYP P450 metabolism. Analogs of 
CJ-15,208 with modification on one of the aromatic residues were synthesized to study and 
improve pharmacokinetic properties. Additionally, CJ-15,208 and [D-Trp]CJ-15,208  were studied 
with in vitro biological barrier models using Madin-Darby canine kidney (MDCK) cells, both wild 
type and a line transfected with the MDR1 gene coding for the efflux protein P-glycoprotein (P-
gp). The peptides’ inhibition of P-gp was assessed using rhodamine 123 efflux, and their efflux 
was assessed by analyzing bidirectional transport across MDCK-MDR1 and MDCK-WT 
monolayers. Evidence of efflux was observed for CJ-15,208 in the transport studies, but the similar 
results in the experiments using MDCK-MDR1 and MDCK-WT cells make it unclear which efflux 
proteins are involved. Preliminary studies suggested that [D-Trp]CJ-15,208 may also be an efflux 
substrate, but additional studies are need to confirm this. The results of these studies will help 
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Chapter I: Literature Review 
 
1.1 Therapeutic potential of polypeptides 
Advances in technology have resulted in increasing identification of new potential drug 
targets. The completion of the human genome project in 2003 and the subsequent genome mining 
was widely expected to result in a radical increase in drug targets and new classes of drugs.1 
However, these new potential leads for drug design have not resulted in increases in the number 
of small molecule leads, with the registration of new chemical entities each year remaining 
relatively constant since 1980.2 While medicinal chemists have more potential therapeutic targets 
than ever before, they also face higher standards for drug safety and efficacy. Additionally, many 
new therapeutic targets involve protein-protein or protein-peptide interactions that can be difficult 
to stimulate or inhibit with small molecules. Increasingly, the pharmaceutical industry is turning 
to macromolecules, including peptide and protein therapeutic agents, to overcome these obstacles. 
Table 1.1 lists some prominent benefits and challenges of therapeutic polypeptides.3, 4 
 
Table 1.1: Therapeutic polypeptides: pros and cons 
Pros Cons 
High selectivity Proteolytic liability 
Potency Low membrane permeability 
Low off-target interactions Short half-life 
Wide range of targets Route of administration 
 
Many pharmaceutically desirable aspects of polypeptides come from their unique 
structures. Peptides and proteins often have increased selectivity and specificity due to their large 
surface areas and potential for polar and non-polar interactions.3 Most protein pockets have 
evolved to interact with complementary sequences of their endogenous peptide or protein 
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counterparts. Polypeptides also have multiple functionalities displayed in specific sequences that 
interfere with interaction with off-target proteins, conferring high selectivity. Peptides also are 
often very potent, activating the conformational changes in their targets required to initiate the 
desired activity. Polypeptides also are less likely to accumulate in tissues as they are often rapidly 
cleared by enzymatic degradation and renal elimination. These features make polypeptides 
desirable targets for the development of safe and potent therapeutics. 
However, while peptides and proteins are an increasing share of the pharmaceutical market, 
they have been limited by delivery challenges. Most therapeutics approved by the Food and Drug 
Administration (FDA) are oral drugs. Oral delivery is attractive because it is less invasive and 
there can be increased ease of administration and compliance compared to injectable drugs.5 
However, the majority of polypeptide therapeutics are currently delivered via subcutaneous, 
intramuscular or intravenous routes. Other routes of administration being explored include 
transdermal, intranasal, and pulmonary delivery, but these strategies have their own drawbacks 
and limitations.5 
One reason why polypeptides are often not orally bioavailable is their impermeability 
across biological barriers. The most commonly used guide for whether a compound will be orally 
bioavailable is Lipinski’s “rule of five,” which offers guidelines for predicting oral bioavailability 
of small-molecule drugs.6   The rule states that molecules are more likely to be orally bioavailable 
if their properties fall within the following parameters:  1. A molecular weight of <500 Da; 2. The 
number of hydrogen bond donors ≤5; 3. The number of hydrogen bond acceptors ≤10; and 4. A 
log P not >5. A number of other variables can be added to this list,7 and guidelines are even stricter 
for prediction of penetration into the Central Nervous System (CNS).8  
Most polypeptides do not fall within the bounds of these rules. Peptides are often much 
larger than 500 Da, and their sizes can hinder their transport across cells, such as those composing 
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the intestinal and blood-brain barriers. Further, polypeptides typically have greater hydrogen 
bonding potential than is recommended by the rule of five, as hydrogen bond donors and acceptors 
are abundant in the peptide backbone and can be present in peptide side chains as well. High 
hydrogen bonding potential can increase the energy costs of passing through lipid membranes. 
However, these hydrogen bond donors and acceptors can also participate in intramolecular bonds, 
increasing the logP of some peptides. Polypeptides can show high logP values, as well as poor 
aqueous solubility, which also hinders their oral delivery. However, it should be noted that these 
guidelines were not generated based on data from therapeutic peptides, and while these properties 
can pose a challenge for oral delivery, they do not contradict it. 
Another challenge to therapeutic use of polypeptides is their rapid clearance. Polypeptides, 
especially those of smaller size, are susceptible to rapid digestion by proteases present in the liver, 
kidneys, and blood.4 This metabolic instability often leads to short half-lives (minutes) and limited 
exposure of polypeptides at their target tissues. 
There has been increased interest in the development of orally bioavailable polypeptide 
therapeutics in recent years, and small peptides have seemed to exhibit the most potential in this 
category. While most polypeptides far exceed 500 Da, peptides of five amino acids or less can be 
within range of this target. Many currently approved peptide therapeutics are relatively small. Of 
the 65 peptide products with <50 amino acids that were on the market in 2010, almost half 
comprised only nine amino acids or less.9 Further, peptides can potentially be made more orally 
bioavailable by cyclization. Peptide cyclization can mask their hydrogen bonding groups by 
forming reversible intramolecular hydrogen bonds, while allowing them to pass through lipid 




One cyclic peptide in particular has been the subject of many permeability studies is 
cyclosporin A (CSA).11-14 This 11-residue cyclic peptide is an orally bioavailable 
immunosuppressant drug, although it requires special formulation due to its low water solubility. 
This natural product has been used as a model for studying structural modifications that can be 
used to enhance oral bioavailability of other cyclic peptides.10 CSA is a macrocyclic peptide, and 
studies comparing the membrane permeability of macrocyclic peptides to their linear counterparts 
suggest that macrocyclization can increase its membrane permeability by eliminating the charges 
due to N- and C- termini and decreasing polarity.15 Studies also suggest that CSA’s permeability 
likely benefits from multiple 3-dimensional conformations that it can adopt.16  
The role of conformational flexibility in passive transport has been explored using a library 
of synthetic macrocyclic hexa- and heptapeptides screened computationally and in a parallel 
artificial membrane permeability assay (PAMPA).16 Peptides that were able to adopt multiple 
conformations, masking their hydrogen bonding groups when in low-dielectric environments and 
exposing them in high-dielectric environments, had higher passive permeabilities than did more 
rigid peptides. In the proposed model, the hydrogen bonding groups in the peptide are exposed to 
the aqueous environment, increasing the peptide’s water-solubility, but in the lipid bilayer 
intramolecular hydrogen bonds form, masking these groups during transport. 
Other modifications, such as N-methylation of the amides, have also been shown to 
increase macrocyclic peptide permeability in cellular assays, likely by activating facilitated 
transport mechanisms. A library of 54 poly-alanine macrocyclic hexapeptides with different N-
methylation patterns were screened using the PAMPA assay and using Caco-2 cell monolayers; 
the peptides with the highest permeability across Caco-2 cells were not permeable across 
PAMPA.17 Caco-2 permeability appeared to be much more influenced by 3-dimensional structure 
than by lipophilicity. 
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These studies indicate that peptide bioavailability can be increased in some cases by 
cyclization and/or by reducing hydrogen bonding by replacing hydrogen bonding groups or 
forming intramolecular hydrogen bonds. Additionally, facilitated transport may be utilized by 
some peptides, but this mechanism is difficult to harness as the peptide’s conformation seems to 
have substantial impact on facilitated transport.18 Moreover, it is essential that such structural 
changes are not detrimental to the peptide’s activity at its target.  
 
1.2 The kappa opioid receptor as a therapeutic target and its small-molecule ligands 
There are three opioid receptors, mu, kappa, and delta, and a related receptor, the 
nociception receptor (NOR).19, 20 These receptors are in the superfamily of G protein coupled 
receptors, which are capable of producing a variety of downstream signaling and pharmacological 
effects. These receptors have been of great historical interest because of their unparalleled potential 
to produce analgesia. More recently, these receptors have been explored as targets in the treatment 
of drug and alcohol abuse and mood disorders.21  
The opioid receptors are found in various tissues including the brain, nervous system and 
intestinal tract. Their endogenous ligands are peptides that are distributed throughout the CNS and 
peripheral tissues and have selectivities for the various opioid receptors. There are many opioid 
peptides and active peptide fragments; the ones that have received considerable attention include 
the endorphins, dynorphins, and enkephalins.22 For an overview of common opioid peptides and 














KOP Dynorphins YGGFLRRIRPKLKWDNQc 
DOP Enkephalins YGGFLd 
NOP Nociceptin FGGFTGARKSARKLANQ 
aβ-Endorphin, bEndomorphin-1 cDynorphin A, dLeu-Enkephalin 
 
The dynorphins are derived from post-translational processing of prodynorphin, an inactive 
precursor protein.23 These peptides have sequences at the N- terminus referred to as the “message” 
that convey agonist activity at opioid receptors as well as sequences at the C-terminus called the 
“address” which enhance affinity for their target receptors.24 They preferentially bind to and 
activate the kappa opioid receptor (KOPr), causing downstream signaling that can occur through 
the inhibition of adenylate cyclase activity or activation of mitogen activated protein kinase.25 In 
addition to analgesia, KOPr activation has been known to play a role in neurological stress 
effects,25 which make both KOPr agonists and antagonists targets of interest for the treatment of 
depression and stress-induced reinstatement of drug and alcohol abuse. 
While KOPr agonists have long been explored as therapies for pain management, this class 
of molecules have differing levels of effectiveness in different models of pain.26 Agonists appear 
to be more effective at blocking responses against mechanical stimuli and chemical irritants than 
against thermal stimuli. KOPr agonists have also shown potent activity in models of visceral pain, 
which appears to be mediated peripherally.27 KOPr activation has the benefit of producing anti-
inflammatory effects as well as analgesia, increasing the therapeutic potential of KOPr agonists.28 
These ligands have the potential to mediate analgesia both through the central nervous system 
(CNS) and peripherally.29 
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KOPr agonists have several potential advantages over currently available mu opioid 
receptor (MOPr) agonists, such as morphine and fentanyl, approved for the treatment of pain. 
Notably, KOPr agonists generally show lower addictive liability compared to MOPr agonists. 
They commonly lack reinforcing effects and have been reported to reduce tolerance to morphine.30 
As the abuse of prescription drugs extracts increasing costs on the US healthcare system, these are 
attractive characteristics for potential analgesics. Additionally, KOPr activation does not cause the 
respiratory depression associated with MOPr activation.31 However, some of effects of central 
KOPr agonism are undesirable, particularly dysphoria and sedation.32, 33 This side effect profile 
has limited the development of centrally active KOPr agonists, although peripherally acting 
agonists are still of considerable interest.29 
There are other applications of KOPr agonists in addition to analgesia. KOPr activation has 
been shown to block the reinforcing effects of alcohol and cocaine. The KOPr-selective agonist 
U50,488 (Figure 1.1) has been shown to attenuate both ethanol34 and cocaine consumption.35 It 
was also effective in suppressing conditioning by both substances of abuse in condition of place 
preference (CPP) models.36, 37 However, it should be noted that U50,488 was observed to 
potentiate cocaine CPP in a time-dependent manner.37 Several studies have suggested that repeated 
administration of KOPr agonists may increase cocaine-seeking behavior by increasing 
extracellular dopamine levels38 and enhance dopamine signaling.39, 40 This time-dependent 
phenomenon is still being studied, but results suggest that KOPr agonists may be more effective 
as acute interventions for cocaine addiction rather than as long term treatments.41 
KOPr antagonists also have potential for clinical development.42 While selective KOPr 
agonists can produce dysphoria, antagonists have shown potential in forced swim studies as 
antidepressants.43 In fact, the KOPr selective antagonist LY2456302 (Figure 1.1) is in clinical 
development as a treatment for depression.44, 45 There is mounting evidence that selective KOPr 
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antagonists may be effective treatments for stress and anxiety.25 KOPr antagonists have also shown 
potential to treat addictions, but at different stages in addiction than agonists. KOPr antagonists 
have been shown to prevent cocaine self-administration46 as well as stress-induced reinstatement 
of cocaine-seeking behavior.47-49 They also reduced operant self-administration in rats selectively 
bred for alcohol preference.45, 50, 51  
It should be noted here that buprenorphine, a MOPr partial agonist, KOPr antagonist/weak 
partial agonist, has been combined with various MOPr antagonists to act as a functional KOPr 
antagonist and is being studied for the treatment of cocaine and opioid addiction.52, 53 Additionally, 
the combination of buprenorphine and samidorphan (a naltrexone derivative) designated ALKS 
5461 is in clinical development for the treatment of major depression.54 
KOPr ligands are being explored for many other therapeutic indications, including nicotine 
addiction.21 Thus, data suggest that KOPr agonists and antagonists have significant potential for 
pharmaceutical development. While some indications such as peripheral pain management could 
be attained with peripherally restricted KOPr ligands, central activity is needed to influence stress, 
mood, and behavior. 
Both peptide and small-molecule ligands for the KOPr have been pursued for clinical 
development, but no KOPr selective ligand has yet been approved. Small molecule KOPr agonists 
include the peripherally selective compounds fedotozine and asimadoline (Figure 1.1), which were 
not effective in clinical trials,55, 56 and centrally acting compounds U50,488, which is primarily 
used as a pharmacological tool, and salvinorin A (Figure 1.1).57 Clinical development of classical 
small-molecule KOPr antagonists such as JDTic (Figure 1.1) could be hampered by their 
exceptionally long durations, lasting weeks to more than a month.58 While shorter-acting small-
molecules antagonists have recently been developed, the mechanism of the long half-lives of 
prototypical KOPr antagonists is still undergoing study.42 There is evidence that these half-lives 
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may be due to prolonged residencies of long-acting antagonists in the brain.59 However, other 
studies suggest that the long durations are due to activation of c-Jun N-terminal kinase (JNK) 
phosphorylation by long-acting KOPr antagonists such as JDTic and nor-binaltorphimine 
(norBNI) rather than by the persistence of these ligands at the receptor. Some long-acting KOPr 
antagonists such as JDTic and norBNI seem to stimulate JNK1 phosphorylation through KOPr 
while some short-acting antagonists do not,60, 61 and the durations of action of the long lasting 
antagonists were shortened after pretreatment with either readily reversible opioid antagonists or 
the JNK inhibitor SP600125. 
 
 





1.3 Peptide ligands of the kappa opioid receptor 
Peptide KOPr agonists and antagonists have been shown to exhibit similar 
pharmacodynamic properties to their small-molecule counterparts, but with different metabolic 
and distribution properties. For the purpose of this discussion, we will focus on peptides with in 
vivo activity. Many reported KOPr selective peptide agonists are analogs of dynorphin A (Dyn A) 
(1-13).62 While this peptide is metabolically unstable, many modifications can be made to increase 
its half-life in vivo, including the incorporation of a reduced peptide bond,63 a D amino acid,64 or 
an N-MeTyr and/or C-terminal amide at the N- and C-termini, respectively.65 Analogs with 
modifications at the termini enhanced morphine analgesia in vivo in morphine-tolerant rats for 3-
4 h after either intravenous or pulmonary delivery.66 The peptide SK-9709 ([D-
Ala2Arg6Ψ(CH2NH)Arg
7]Dyn A-(1-8) amide) (Figure 1.2), which contains a reduced amide bond 
between Arg6 and Arg7, has also shown antinoniceptive activity in vivo.63 SK-9709 shows equal 
or greater activity than U50,488 after systemic (subcutaneous, s.c.) in mice in both the acetic acid 
stretching and hot-plate assays. While in vitro data indicates that SK-9709 has a 15-fold higher 
selectivity for KOPr over MOPr, its in vivo opioid agonist activity seems to be mediated by both 
receptors, as both norBNI, administered intrathecal (i.t.) and the MOPr antagonist β-FNA, 





Figure 1.2: Examples of peptide KOPr ligands 
  
The activities of peptide KOPr agonists are dependent on whether they are centrally active 
or peripherally selective. One Dyn A analog that can penetrate the CNS is E-2078 ([NMeTyr1, 
NMeArg7,D-Leu8]Dyn A-(1-8) N-ethyl amide, Figure 1.2).67 This peptide has been studied in 
rodents,68-70 monkeys,71-73 and humans,74, 75 and appears to induce analgesic effects primarily 
through KOPr.69 The peptide and its radiolabeled analog were detected in mice brains after a brain 
perfusion study68 and monkey brains after systemic administration, respectively.71 An in vitro 
blood-brain barrier (BBB) model using the bovine brain microvessel endothelial cell (BBMEC) 
model indicated that [125I-Tyr]E-2078 was transported across the BBB by absorptive-mediated 
endocytosis.76 In contrast, FE200665 (CR 665 or JNJ 38488502, H-D-Phe-D-Phe-D-Nle-D-Arg-
NH-4-picoly, Figure 1.2,) appears to be peripherally selective,77 thereby limiting centrally 
mediated side effects such as sedation or locomotor impairment. This compound is currently under 
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clinical development by Johnson and Johnson,78 and while FE200665 is not itself orally 
bioavailable, its analogs have yielded several orally bioavailable leads.79 
Peptides have shown promise as KOPr antagonists as well. Dyn A analogs with 
antagonistic activity generally have modifications in the N-terminal Tyr-Gly-Gly-Phe “message” 
sequence80 and include peptides without a basic amine terminus,81, 82 Pro3 derivatives,83, 84 and 
cyclic derivatives.85, 86 Arodyn (Figure 1.2) is a linear peptide that has in vivo KOPr antagonist 
activity following i.c.v. administration in mice, blocking the antinociceptive effects of U50,488 in 
the 55 °C warm water tail withdrawal assay.48 It is also effective in blocking stress-induced 
reinstatement of cocaine-seeking behavior in a CPP model in mice, but is rapidly metabolized in 
blood,87 limiting systemic administration. A peptide with greater metabolic stability is zyklophin 
(Figure 1.2), an analog that is cyclized through two of its residues in the “address” sequence.86 Not 
only does it have peripheral antagonist activity after systemic administration, 88 but it is also able 
to block the antinociceptive activity of centrally administered U50,488, suggesting that is able to 
penetrate the BBB. Further, these peptide KOPr antagonists show more finite duration of action 
than classical small-molecule antagonists, for example zyklophin88 exhibits a duration of action of 
about 12 h rather than the weeks observed for norBNI and JDTic.41 These in vivo studies of these 
peptides demonstrate the pharmacological potential of peptide ligands of KOPr. 
 
1.4 CJ-15,208 and [D-Trp]CJ-15,208: Pharmacodynamics, pharmacokinetics, and structure-
activity relationships 
The macrocyclic peptide natural product CJ-15,208 (cyclic[Trp-Phe-D-Pro-Phe], Figure 
1.3) was isolated from a fermentation broth of Ctenomyces serratus ATCC15502.89 It was reported 
to bind to KOPr with modest affinity and selectivity and antagonize a KOR agonist in vitro. 
Because the stereochemistry of the tryptophan residue in the natural product was not known, the 
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Aldrich research group optimized the cyclization conditions and synthesized both the L-Trp and 
D-Trp isomers for testing.90, 91 While the optical rotation of only the L-Trp isomer was consistent 
with the natural product, both isomers exhibited similar nanomolar affinity for KOPr. Both isomers 
showed in vitro KOPr antagonism in a guanosine-5'-(3-thiotriphosphate) (GTPγS) binding assay,92 
but have displayed surprisingly different activity profiles in vivo.92 
 
 
Figure 1.3: CJ-15,208 and [D-Trp]CJ-15,208 
 
The D-Trp isomer (Figure 1.3) has shown predominantly KOPr antagonist activity in vivo 
with only minimal agonist activity at high doses.49, 92 It exhibits short-acting antagonist activity, 
and is able to block the antinociceptive activity of U50,488 administered systemically 
(intraperitoneal, i.p.) after various routes of administration: central (3 nmol i.c.v., <18 h duration 
of action), peripheral (10 mg/kg s.c., <18 h duration of action), and oral (10 mg/kg p.o., <12 h 
duration of action).49, 92 Further, it blocks the antinociceptive activity of U50,488 administered 
centrally (i.c.v.) after oral administration (30 mg/kg p.o., <6 h duration of action), indicating its 
ability to cross the BBB with no impairment of locomotor activity. The CNS penetration of orally 
administered [D-Trp]CJ-15,208 was verified by detection of this peptide in the brain by liquid 
14 
 
chromatography tandem mass spectrometry (LC-MS/MS). Additionally, orally administered [D-
Trp]CJ-15,208 prevented stress-, but not cocaine-induced, reinstatement of extinguished cocaine-
seeking behavior in mice in a CPP assay, consistent with its KOPr antagonist activity. 
The L-Trp isomer (the natural product) has shown both agonist (antinociceptive) activity 
and short-acting KOPr antagonist activity in vivo. It exhibits short-acting antagonist activity and 
is able to block the antinociceptive activity of U50,488 administered systemically (i.p.) after 
central (3 nmol i.c.v., <18 h duration of action) and oral administration (10 mg/kg p.o., <12 h 
duration of action).92, 93 CJ-15,208 also shows opioid agonist activity mediated by both KOPr and 
MOPr after oral administration (60 mg/kg p.o., <3 h duration) without affecting locomotor activity. 
The peptide shows CNS activity after oral administration, antagonizing the antinociceptive activity 
of U50,488 administered centrally (i.c.v.). Interestingly, orally administered CJ-15,208 is able to 
prevent both cocaine- and stress-induced reinstatement of extinguished cocaine-seeking behavior 
in the CPP assay in a time- and dose-dependent manner.  
These peptides have shown unusual structure-activity relationships. While small 
modifications can have radical effects on activity profiles, some analogs with significant 
substitutions retain activity. Alanine scan analogs of both isomers were generated and tested in 
vivo and in vitro to determine the residues involved in mediating activity. Each of the alanine 
analogs of CJ-15,208 retained opioid agonist and KOPr antagonist activity of the parent compound 
after i.c.v. administration in an antinociceptive assay, but the opioid agonism of the analogs was 
predominately mediated by MOPr.94 The Ala3 analog showed the most potent agonist activity. The 
Ala3 and Ala1 analogs had antagonist activity comparable to the parent compound.  
In contrast to the current parent peptide, alanine substitution for any residues of [D-Trp]CJ-
15,208 resulted in antinociceptive (opioid agonist) activity in this assay following i.c.v. 
administration.95 The in vivo KOPr antagonist activity of the parent peptide was retained in all 
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analogs except the D-NMeAla2, suggesting that the D-Pro residue is important for KOPr antagonist 
activity. Further, analogs with alanine substituted for the D-Trp or Phe1 positions prevented stress-
induced, but not cocaine-primed, reinstatement of cocaine CPP after i.c.v. pretreatment. It should 
also be noted that the alanine scan analogs of the two isomers exhibited similar in vitro profiles 
that were not indicative of their in vivo activities. 
The Dolle laboratory synthesized a series of [D-Trp]CJ-15,208 analogs and evaluated their 
binding and selectivity exclusively in vitro.96 This study indicated that linear analogs of the cyclic 
peptides had little appreciable affinity for the opioid receptors. In a series of [D-Trp]CJ-15,208 
analogs with substitutions on either phenylalanine residue, peptides containing tyrosine substituted 
for phenylalanine displayed a substantial loss in KOPr affinity. Analogs incorporating m-Tyr 
residues retained higher KOPr affinity, but lost selectivity over MOPr. Substitution at the 4’ 
position on either Phe residue with either a methoxy or fluorine resulted in modest affinity at KOPr.  
These macrocyclic peptides also have acceptable pharmacokinetic properties in in vitro 
models. CJ-15,208 and its D-Trp analog show remarkable stability in plasma and whole blood for 
at least 20 h,97 indicating resistance to proteases. However, studies in liver microsomes indicate 
susceptibility to oxidation, presumably through cytochrome p450 (CYP-P450) enzymes, resulting 
in relatively short half-lives for both CJ-15,208 (60 min) and especially [D-Trp]CJ-15,208 (12 
min). Other cyclic peptides, including cyclic prodrugs of [D-Ala2, D-Leu5]encephalin (DADLE), 
a pentapeptide opioid agonist primarily acting through delta opioid receptor (DOPr), have been 
shown to be unstable in rat and guinea pig liver microsomes, showing nearly complete degradation 
after 15 min.98 Interestingly, studies of DADLE and its capped and cyclic analogs indicate that the 
cyclized peptides were less susceptible to hydrolytic metabolism, possibly due to high protein 
binding,99 but more susceptible to metabolism by CYP P450 enzymes than their linear 
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counterparts.98 As CYP P450 enzymes are present both in liver and brain tissue,100, 101 
susceptibility to oxidative metabolism can affect central activity. 
 
1.5 Overview of the blood-brain barrier 
While peripherally selective KOPr agonists can be used in the treatment of some forms of 
pain, central activity is required for the treatment of drug and alcohol addiction. However, few 
CNS drug candidates make it to the market. About 10% of all therapeutic compounds that enter 
phase I clinical trials become marketed drugs compared to only 3-5% of centrally acting agents.102 
Part of the reason oral CNS agents often fail in clinical trials is because of the BBB. The BBB is 
a complex cellular construct that separates brain matter from the systemic circulation. It acts as a 
physical barrier to protect the brain’s homeostasis and keep toxins out of the CNS, and represents 
a serious challenge for centrally acting drugs. Approximately 98% of small molecule drugs and 
almost all large molecule neurotherapeutics cannot cross the BBB.103 This barrier has eliminated 
many neuroactive peptides and biologics with promising activity from clinical use.8  
The BBB has a diverse set of components that can either hinder or facilitate drug transport 
into the CNS. The BBB is involved is some metabolism, mostly carried out by aminopeptidases, 
endopeptidases, and cholinesterases.104 Drugs can also be metabolized in the brain by CYP-
P450s.105 Paracellular transport of hydrophilic drugs between the brain endothelial cells is typically 
prevented by tight junctions and adherens junctions between the cells.106 Tight junctions are 
formed by a network of intercellular proteins, including occludin, zonula occludens, and claudins, 
between adjacent cells to form a continuous barrier between the cells.106 Adherens junctions from 
a slightly more penetrable barrier than tight junctions, and are formed between cells through the 
integral membrane proteins VE-cadherin and PECAM-1. The actin cytoskeleton, to which many 
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of these integral membrane proteins are anchored, has also been shown to play a role in the 
integrity of these junctions.107 
Small, relatively lipophilic molecules are likely to passively diffuse across the BBB,108 
which is the most common means of transport into the CNS of centrally acting therapeutics 
approved by the FDA.109 Passive diffusion is a process in which the aqueous solvent shell around 
the compound is dissipated and it dissolves into a lipid bilayer; another aqueous solvent shell must 
form around the compound after passing through to the other side of the membrane. Because of 
the differences between the intestinal barrier and the BBB, Lipinski’s rule of 5 has been modified 
to predict CNS penetration. To optimize passive diffusion into the brain, small molecule drugs 
should meet the following criteria: Molecular weight ≤400, LogP ≤5, hydrogen bond donors ≤3, 
and hydrogen bond acceptors ≤7.110 While most peptides do not fall within these ranges, these rule 
were not constructed around polypeptide CNS permeability. 
While it is possible for polypeptides with a molecular weight up to 4.1 kDa to passively 
diffuse across the BBB,111 many researchers are exploring strategies to deliver polypeptides into 
the brain that take advantage of the BBB’s active and facilitated transporters. Receptor-mediated 
transport is responsible for transporting larger peptides and proteins like transferrin and insulin 
across the BBB.112 Opioid peptides have also been shown to be actively transported via 
endocytosis.76 
Passive transcellular transport of some drugs across the BBB can be hindered by efflux 
proteins. Efflux proteins are integral membrane proteins that are highly expressed in the BBB and 
actively transport a broad range of compounds, particularly potentially harmful chemical entities, 
out of the CNS.113 These effective proteins include ATP-binding cassette (ABC) transporters, such 
as P-glycoprotein (P-gp), and the breast cancer resistant protein (BCRP).114 P-gp is responsible for 
the ATP-dependent efflux of many lipophilic, amphipathic, and cationic drugs, and is the most 
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commonly examined efflux protein in drug design. Inhibitors of P-gp include verapamil, CSA and 
quinidine. Several cyclic peptides have been shown to be effluxed by both P-gp and BCRP,115 
limiting their central exposure. Conversely, P-gp efflux has been used as a strategy to restrict 
therapeutics to the periphery. For example, P-gp has reduced the negative side effects caused by 
central exposure of both CSA116 and small molecule KOPr agonists.117 
 
1.6 Assays for transport 
Passive diffusion assays are the fastest and most cost efficient methods for assessing 
transport early in compound design.102 These include immobilized artificial membrane (IAM) 
columns, the parallel artificial membrane permeability assay (PAMPA), and PAMPA-BBB. IAM 
columns are made up of phospholipids bonded to the silica gel. Liquid chromatography using these 
columns gives a retention time that has been shown to be a better predictor than logP for CNS 
penetration.118 However, this method does not give a permeability constant. PAMPA allows for 
the measurement of passive diffusion across an artificial bilayer membrane made of phospholipids. 
This model can be modified to better mimic the BBB by using porcine polar brain lipid extracts to 
form the membrane, in which case the assay is termed PAMPA-BBB.119 The PAMPA assays and 
the IAM column are high throughput and very reproducible, but they do not model efflux or 
facilitated transport. 
Compound transport can also be measured in assays that are designed to mimic the BBB. 
Monolayers of primary cultures of brain endothelial cells, such as BBMEC, have shown utility in 
studying peptides.120, 121 However, formation of tight junctions can be variable and must be closely 
monitored to maintain reproducibility. A new assay attempts to overcome these difficulties by 
using a stem-cell based model of the BBB.122 Lippmann et al. co-cultured both human embryonic 
stem cells and human induced pluripotent stem cells with astrocytes to induce BBB characteristics. 
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The stem cells were observed to form tight junctions and express sufficient amounts of transporters 
to serve as a representative model of the BBB. 
Other in vitro models can be used to model compounds’ potential penetration into the 
CNS.102 The Caco-2 and Madin-Darby canine kidney (MDCK) cell lines are accepted in vitro 
models of the intestinal barrier. Despite the fundamental differences between these cell lines and 
those found in the BBB, they can be used to predict whether candidates will be substrates of efflux 
proteins that are found in the BBB.13 Caco-2 cells express sufficient levels of efflux proteins for 
study, and efflux protein genes, such as the P-gp gene MDR1, can be transfected into MDCK cells. 
Since both cell lines are polar, the ratio of compound transported from the apical (A) to the 
basolateral (B) side compared to from B to A can be used as an indication of whether the compound 
is a substrate for efflux proteins. The exact proteins involved in efflux can be deduced by 
performing efflux inhibitor studies.  
Both in vivo and in vitro models of the BBB have been used to study opioid peptides with 
in vivo activity. A number of opioid peptides have been studied for BBB permeability. Enkephalin 
analogs with permeability and activity in the CNS have been designed and tested. Several 
strategies were employed for improving their transport across the BBB. Glycosylation on the 
cyclic opioid peptide cyclo[D-Cys2,5,Ser6,Gly7]enkephalin with various sugar moieties improved 
in situ brain uptake in rats by up to 98%.123 The glycosylation was shown to significantly lower 
LogP and slightly decreased peptide binding to bovine serum albumin. In other cases, increasing 
the LogP through the introduction of halogens improved peptide transport.124 For example, the 
peptide biphalin ([Tyr-D-Ala-Gly-Phe-NH]2), a dimeric enkephalin analog with activity at both 
the MOPr and DOPr,125 showed both passive diffusion and active transport via the large neutral 
amino acid carrier in in situ brain perfusion studies.126 Halogenated biphalin analogs were screened 
20 
 
in in vitro and in situ models of the BBB, and a chlorohalogenated analog showed both increased 
uptake and biological stability.127  
Facilitated transport was also observed in studies of opioid peptides. The peptide [D-
penicillamine2,5]enkephalin (DPDPE) is a cyclic DOPr agonist that displayed passive diffusion in 
a primary endothelial cell culture model of the BBB, but its transport greatly increases in the 
presence of insulin both in vitro and in situ.126, 128 It was postulated that its transport might be 
augmented by the transcytosis induced by insulin’s receptor-mediated transport across the BBB. 
Several other cyclic peptides have shown permeability in models of the BBB. The 
Borchardt lab produced a series of cyclic prodrugs of the peptide DADLE (H-Tyr-D-Ala-Gly-Phe-
D-Leu-OH), an enkephalin analog, and studied their transport across monolayers Caco-2129-131 and 
MDCK-MDR1 cells.115 Many of the cyclic peptides had improved permeability compared to the 
parent compound,130, 131 but the transport of some of the analogs appeared to be limited by efflux,129 
especially by P-gp.115 Studies in Caco-2 monolayers suggested that CJ-15,208 was an efflux 
substrate,132 but the efflux proteins involved have not been identified. 
 
1.7 Importance of current work 
While drug addiction continues to represent a burden on the U.S. economy, there are 
currently no FDA approved pharmaceutical treatments for cocaine addiction, and the most 
commonly prescribed analgesics have agonist activity at MOPr, which is associated with addictive 
liability. KOPr agonists have potential as non-addictive analgesics, and both KOPr agonists and 
antagonists have potential in the treatment of cocaine addiction. While the clinical applications of 
many small-molecule KOPr ligands have been limited by side effects, peptide ligands could be 
promising leads, however their pharmacokinetic properties must be assessed, and possibly 
modified by incorporating structural changes. 
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The experiments in mice discussed above indicate that CJ-15,208 has antinociceptive 
activity and can block cocaine-induced reinstatement of cocaine CPP, and that both it and [D-
Trp]CJ-15,208 can prevent stress-induced reinstatement of cocaine CPP. Further, these peptides 
are orally bioavailable, cross the BBB, and do not induce side effects such as sedation. However, 
large doses of these peptides are required for oral activity, and bioavailability may be limited by 
rapid oxidative metabolism and/or efflux at the intestinal and/or blood-brain barriers. 
In this study, CJ-15,208 and [D-Trp]CJ-15,208 are evaluated in MDCK cells, both in wild 
type (WT) cells and cells transfected with the P-gp gene MDR1, to determine their transport and 
interactions with the efflux protein P-gp. Identifying interactions with specific efflux proteins can 
aid in the design of future analogs. We also synthesized deuterated probes to examine oxidative 
metabolism patterns of CJ-15,208 and [D-Trp]CJ-15,208 and the effects of structure modification 
on opioid activity. This information could aid in the design of metabolism-resistant analogs. 
Analogs of CJ-15,208 and [D-Trp]CJ-15,208 incorporating fluorine, hydroxyl, and methoxy 
groups into their aromatic residues were synthesized to potentially improve absorption and 
distribution properties. These compounds are being screened for in vivo activity. 
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Our research focuses on the design and synthesis of orally active kappa (κ) opioid receptor 
(KOPr) ligands for the treatment of drug and alcohol addiction. For a general overview of the 
KOPr, its ligands, and their potential indications in pain, addiction, and depression, as well as 
background on our lead compound CJ-15,208, please refer to chapter 1. 
The natural product macrocyclic tetrapeptide CJ-15,208 was reported to be a KOPr 
antagonist with modest affinity and selectivity for the KOPr.1 We synthesized both the L- and D-
Trp isomers of CJ-15,208 in our laboratory.2, 3 The L-Trp isomer (the natural product) showed 
both agonist (antinociceptive) activity and short-acting KOPr antagonist activity in vivo,4 while 
the D-Trp isomer showed predominantly KOPr antagonist activity in vivo.5 Both isomers exhibited 
opioid activity in the central nervous system (CNS) after oral administration in mice.5, 6 However, 
this required relatively high doses (30-60 mg/kg p.o.), and their antagonist activity was relatively 
short (<12 h). Our aim is to lower the dose necessary for these peptides to mediate central activity 
after oral administration while maintaining a desirable duration of action (preferably 12-24 h).  
There are several pharmacokinetic properties that could be modulated to improve the 
bioavailability of these peptides. The first is stability to metabolism. While both peptides are stable 
to proteases in human plasma and whole blood, studies in mouse liver microsomes indicated that 
both peptides are susceptible to oxidation, presumably by cytochrome P450 (CYP-P450) enzymes, 
showing half-lives of about 60 min for the L-Trp isomer and 12 min for the D-Trp isomer.7 
Deuterated analogs can be useful in studying metabolites and patterns in metabolism. Further, in 
vivo resistance to oxidation can be improved by the incorporation of fluorine in appropriate 
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positions.  Another property that can be modified is hydrophobicity, as CJ-15,208 and its D-Trp 
isomer both have very low aqueous solubility.8 Structural modifications at hydrophobic residues 
such as Trp have been shown to improve the solubility of cyclic peptides.9 
Therefore, this research focusing on improving the oral bioavailability of CJ-15,208 and 
its D-Trp analog has three components. The first was to synthesize deuterated analogs of the two 
leads as internal standards for use in studying the oxidative metabolism patterns. The second is to 
attenuate oxidative metabolism by incorporating fluorine into the aromatic residues of the two 
peptides. The third is to synthesize potential metabolites or analogs of metabolites by incorporating 
a hydroxyl group at the 5 position on Trp or a hydroxyl or methoxy functionality into one of the 
Phe residues. These analogs may be useful in elucidating the effects of oxidized metabolites on in 
vivo activity. They also have the potential benefit of increased aqueous solubility due to the 
incorporation of a polar functionality, which decreases the clogP from 5.0 (CJ-15,208) to 4.3 
(hydroxylated analogs). The deuterated probes will be used for analysis in mouse liver 
microsomes, and the analogs incorporating fluorine, hydroxyl, and methoxy groups will be 
screened for activity in vivo and for affinity and selectivity in vitro. 
 
2.2 Results and discussion 
2.2.1 Fmoc protection 
Fmoc (9-fluorenylmethoxycarbonyl) protection was required of specialty amino acids 
obtained in their free amino acid form, including L-phenyl-d5-alanine, L-3-methoxyphenylalanine, 
L-m-tyrosine, 5-hydroxy-L-tryptophan, L-tryptophan-2′,4′,5′,6′,7′-d5, D-tryptophan-2′,4′,5′,6′,7′-
d5, 5-fluoro-D-tryptophan, and 5-fluoro-D/L-tryptophan. All of these amino acids were protected 
using 9-fluorenylmethyl N-succinimidyl carbonate (Fmoc-OSu). Other specialty amino acids were 
obtained in the Fmoc-protected form.  
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The solubilities and stabilities of the tryptophan analogs differed from those of the 
phenylalanine analogs, which necessitated different reaction conditions. The procedure for 
protecting the tryptophan analogs was modified from Lawson et al.10 The solvent used for the 
reaction was tetrahydrofuran (THF):saturated NaHCO3 (1:1), and the reaction was quenched after 
2 h to prevent degradation of the tryptophan side chain. Additionally, 5-hydroxy-L-tryptophan is 
susceptible to photodegradation, and therefore its protection was performed under argon gas and 
with the reaction vessel wrapped in aluminum foil. Yields of Fmoc protection of the Trp analog 
amino acids ranged from 24-90%. 
The procedure for protecting the phenylalanine analogs was modified from Kang et al.11 
The solvent used for the reaction was dioxane: H2O (1:1) with 3 equivalent NaHCO3. Purification 
of the Phe analog amino acids was limited by the co-elution of unreacted Fmoc-OSu with the 
desired products. This difficulty was circumvented by using a small excess of the amino acid (1.1 
equiv) and allowing the reactions to proceed for longer times, up to 15 h. Yields of Fmoc protection 
of the Phe analog amino acids ranged from 24-48%. 
 
2.2.2 Peptide synthesis 
The synthesis of 16 macrocyclic tetrapeptides was modified from previously reported 
procedures.3, 12 The analogs of CJ-15,208 were synthesized on a relatively small scale, obtaining 
1-110 mg (3-57% yield) of pure peptide (≥97% pure). Analogs with modifications at the Trp 
residue had linear precursor with the sequences R1*-Phe-D-Pro-Phe were prepared, where R1* was 
L-Trp(5-OH), L-Trp(d5), D-Trp(d5), Trp(5-F), or D-Trp(5-F), while for analogs with mono-
substitutions at Phe1 or Phe3 the linear precursor sequences synthesized were Trp*-R2-D-Pro-R3, 
where R2 or R3 was Phe(d5), Phe(3-F), Phe(4-F), m-Tyr, m-Tyr(Me), or Tyr(Me). An old batch of 
a high load chlorotrityl chloride resin (0.84 mmol/g) was observed to result in low yields of linear 
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peptides. It was used for the synthesis of some analogs (peptides 1a-4a, 6a-8a, Table 2.4) which 
had lower yields (5-60%) and in some cases lower purity (76.5% for peptide 8a). The stabilities 
of the analogs to heat were unknown, so cyclizations were performed for 37.5-70.5 h at room 
temperature for these initial studies. 
 










Linear Precursor Sequence 
1 cyclo[Trp(5-OH)-Phe-D-Pro-Phe] 1a Trp(5-OH)-Phe-D-Pro-Phe-OH 
2 cyclo[Trp(d5)-Phe-D-Pro-Phe] 2a Trp(d5)-Phe-D-Pro-Phe-OH 
3 cyclo[D-Trp(d5)-Phe-D-Pro-Phe] 3a D-Trp(d5)-Phe-D-Pro-Phe-OH 
4 cyclo[Phe(d5)-D-Pro-Phe-Trp] 4a Phe(d5)-D-Pro-Phe-Trp-OH 
5 cyclo[Phe-D-Pro-Phe(d5)-Trp] 5a Phe-D-Pro-Phe(d5)-Trp-OH 
6 cyclo[Trp(5-F)-Phe-D-Pro-Phe] 6a Trp(5-F)-Phe-D-Pro-Phe-OH 
7 cyclo[D-Trp(5-F)-Phe-D-Pro-Phe] 7a D-Trp(5-F)-Phe-D-Pro-Phe-OH 
8 cyclo[Phe(3-F)-D-Pro-Phe-Trp] 8a Phe(3-F)-D-Pro-Phe-Trp-OH 
9 cyclo[Phe-D-Pro-Phe(3-F)-Trp] 9a Phe-D-Pro-Phe(3-F)-Trp-OH 
10 cyclo[Phe(4-F)-D-Pro-Phe-Trp] 10a Phe(4-F)-D-Pro-Phe-Trp-OH 
11 cyclo[Phe-D-Pro-Phe(4-F)-Trp] 11a Phe-D-Pro-Phe(4-F)-Trp-OH 
12 cyclo[m-Tyr-D-Pro-Phe-Trp] 12a m-Tyr-D-Pro-Phe-Trp-OH 
13 cyclo[m-Tyr(Me)-D-Pro-Phe-Trp] 13a m-Tyr(Me)-D-Pro-Phe-Trp-OH 
14 cyclo[Phe-D-Pro-m-Tyr(Me)-Trp] 14a Phe-D-Pro-m-Tyr(Me)-Trp-OH 
15 cyclo[Tyr(Me)-D-Pro-Phe-Trp] 15a Tyr(Me)-D-Pro-Phe-Trp-OH 
16 cyclo[Phe-D-Pro-Tyr(Me)-Trp] 16a Phe-D-Pro-Tyr(Me)-Trp-OH 
 
Crude linear peptides were used for cyclization. The two diastereomeric linear precursor 
peptides 6a and 7a resulting from incorporating racemic 5-fluoro-D/L-tryptophan were not 
separated, and instead the resulting cyclic peptides were separated after cyclization. 5-Fluoro-D-
tryptophan was used to synthesize a standard for peptide 7, which allowed unambiguous 
identification of the two diastereomeric macrocyclic tetrapeptides 6 and 7 after purification. 
It should be noted here that the peptides 1 and 12 were synthesized using amino acids with 
unprotected hydroxyl groups on their side chains. These residues were incorporated at the N-
termini of the linear peptides, insuring the hydroxyls would not interfere with the coupling 
reactions. These hydroxyls were not observed to produce any by-products during the cyclization 
reaction that were not observed for the other analogs. 
 Peptide 1, which contains 5-hydroxy-Trp, was found to be light sensitive and underwent 
oxidative degradation. It was protected from light with aluminum foil during synthesis of the 
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precursor linear peptide, cyclization, and lyphilization, and the cyclization reaction was also 
performed under argon gas. The crude linear peptide and cyclic peptide were stored under argon 
gas, as the unlyophilized (oil form) linear or cyclic peptides stored under nitrogen and protected 
from light showed evidence of degradation (red coloring) after 1 week. Lyophilization and storage 
at 0 oC was found to slow degradation. The oxidative degradation of peptide 1, its linear precursor, 
and Fmoc-5-hydroxy-Trp itself resulted in the formation of at least one red-colored polar product. 
High-performance liquid chromatography (HPLC) analysis of peptide 1 that had undergone 
moderate oxidative degradation showed three less polar side products. The structures of these side 
products have not yet been elucidated. 
 
2.2.3 Purification of macrocyclic tetrapeptides 
The cyclic peptides were first purified by normal-phase flash chromatography as reported 
in previous studies. However, many of the peptides co-eluted with a yellow-colored HATU (2-
(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) by-product, which 
was less polar than the L-Trp analogs but more polar than the D-Trp analogs on thin layer 
chromatogram (TLC). This by-product was also observed in previous syntheses of macrocyclic 
tetrapeptides. Silica gel chromatography was not successful in separating some of the cyclic 
peptides from the HATU by-product using either hexanes/ethyl acetate (EtOAc) or 
dichloromethane (DCM)/methanol as the solvent systems. This resulted in low yields of pure 
product for peptides 3 (4%) and 7 (3%), which also had the added difficulty of very small-scale 
syntheses (≤50 mg linear precursor) and which did not undergo further purification steps. Because 
most of the L-Trp macrocyclic tetrapeptides have limited solubility, selective precipitation was 
utilized for some peptides to prevent loss of the product by further chromatography. The HATU 
by-product was found to be more soluble in all of the solvents utilized than the cyclic peptides.  
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Some peptides, especially peptide 12, were partially soluble in the solvents utilized, resulting in 
lower yields (4% for peptide 12). Impure peptide that did not precipitate was concentrated or 
lyophilized for further purification. D-Trp analogs generally have greater solubility, so this 
procedure was not used for peptides 3 or 7. 
 
2.3 Conclusions and future studies 
In conclusion, we designed and synthesized a series of macrocyclic CJ-15,208 analogs. 
Peptides incorporating deuterated Phe or Trp residues will be utilized to study oxidative 
metabolism in mouse liver microsomes. Other analogs are undergoing testing for in vivo activity, 
and the results of these studies will indicate how well modifications at each of the Phe residues are 
tolerated. In vitro testing will be performed to determine the affinities and selectivities of these 
peptides for the KOPr. 
 
2.4 Experimental section 
2.4.1 Materials 
Reagents for peptide synthesis were obtained from the following sources: Fmoc-protected 
amino acids, 2-chlorotrityl chloride resin, and coupling reagents HATU (2-(1H-7-azabenzotriazol-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) and PyBOP (benzotriazol-1-
yloxytripyrrolidinophosphonium hexafluorophosphate) were obtained from Novabiochem 
(EMD), San Diego, CA; 1-hydroxybenzotriazole and N,N-diisopropylethylamine (DIEA) were 
from Fluka, Milwaukee, WI; TFA was purchased from Pierce, Rockford, IL; and HPLC-grade 
solvents were from Fisher Scientific, Pittsburgh, PA. Deuterated amino acids were obtained from 
C/D/N Isotopes Inc. (Pointe-Claire, Quebec, Canada). Other specialty amino acids were obtained 
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from Chem-Impex International Inc. (Wood Dale, IL). Standard Fmoc-protected L- and D- amino 
acids were obtained from Novabiochem ((EMD), San Diego, CA). 
 
2.4.2 Fmoc protection of phenylalanine analogs 
The experimental procedure was modified from Kang et al.11 L-Phenyl-d5-alanine, L-meta-
methoxyphenylalanine, or L-meta-tyrosine (1.1 equiv) was dissolved in dioxane:H2O (1:1) with 
Fmoc-OSu (1 equiv) and NaHCO3 (3 equiv). The reaction was stirred at room temperature for 3-
15 h (3 h for Fmoc-Phe(d5)), monitored with TLC, and was then quenched with 20 mL each ice 
and chloroform, and the pH adjusted to 3 using concentrated HCl. The product was extracted using 
chloroform (3 X 50 mL) and concentrated under low pressure. The crude product was then 
dissolved in EtOAc (150 mL), and the solution washed with saturated NaHCO3 solution (6 X 100 
mL). The aqueous layer was adjusted to pH 4 using concentrated HCl; a white precipitate formed 
which was then filtered, dissolved in EtOAc (250 mL), and the solution washed with dilute HCl 
(pH 3, 3 X 50 mL). The product was dried over MgSO4, filtered, and concentrated under low 
pressure. The protected amino acid was then purified over preloaded 24 g silica gel columns at 35 
mL/min with a solvent system of 0-15% MeOH in DCM or 20-80% EtOAc in hexanes (Fmoc-
Phe(d5)) over 15 min or 25 min (Fmoc-Phe(d5)) using a Teledyne Combi Flash Rf monitored at 
254 and 280 nm. Details of the reaction and purification conditions, yields, and spectral data can 


































249 48 12.52/97.4 454.18 (454.18) 
Fmoc-L-m-Tyr 500 40/15 
0-15% MeOH 
in DCM 






297 31 12.40/91.3 415.17 (415.17) 
aDioxane:H2O (1:1). 
bHPLC analysis using a solvent system of 30-70% Solvent B over 40 min 
(Solvent A= H2O; Solvent B= MeCN, both containing 0.1% TFA). 
cPurity is being determined. 
 
 
2.4.3 Fmoc protection of tryptophan analogs 
The experimental procedure was modified from Lawson, et al.10 One equivalent of 
unprotected tryptophan analogs, including 5-hydroxy-L-tryptophan, L-tryptophan-2′,4′,5′,6′,7′-d5, 
D-tryptophan-2′,4′,5′,6′,7′-d5, 5-fluoro-D-tryptophan, or 5-fluoro-D/L-tryptophan, and Fmoc-OSu 
(1.2 or 2 equiv) were suspended in THF:saturated NaHCO3 (1:1). The solvents were degassed for 
5-hydroxy-L-tryptophan, and the reaction with this amino acid was kept under argon gas and 
protected from light with aluminum foil. The reaction was stirred at room temperature for 2 h. The 
THF was removed under low pressure, and the pH of the resulting aqueous suspension adjusted to 
< 3 using concentrated HCl. The aqueous solution was extracted with EtOAc (2 X, 150 mL). The 
organic layer was dried over MgSO4 and concentrated at low pressure.  
The amino acids were then purified over silica gel using a Teledyne Combi Flash Rf system 
with monitoring at 254 and 280 nm. Fmoc-L-Trp(d5) and Fmoc-L-Trp(d5) were purified over 
preloaded 24 g silica gel columns at 35 mL/min using 20-100% EtOAc in hexanes over 25 min. 
Fmoc-D-Trp(5-F) and Fmoc-DL-Trp(5-F) were purified over a preloaded 24 or 4 g (Fmoc-D-
Trp(5-F)) silica gel column at 35 mL/min of 18 mL/min using (Fmoc-D-Trp(5-F)) 20-100% 
EtOAc in hexanes over 25 min. Fmoc-L-Trp(5-OH) was purified over preloaded 24 g silica gel 
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columns at 35 mL/min using 25-100% EtOAc in hexanes over 25 min. The amino acid was then 
re-dissolved in H2O:MeCN (approximately 3:1, 4-8 mL), and the solutions transferred to 
scintillation vials, frozen and lyophilized. (Solutions of Fmoc-5-hydroxy-L-tryptophan was 
covered with aluminum foil during lyphilization.) Specific reaction and purification conditions, 
analytical, and spectral data can be found in Table 2.3. 
 




















































564.8 56 4.03/96.9d,e 465.14(465.18) 
aThe reaction was performed protected from the light under argon gas. bTHF:saturated NAHCO3 
(1:1), cUPLC analysis using a solvent system of 40-80% Solvent B over 14 min (Solvent A= 
H2O; Solvent B= MeCN, both containing 0.1% TFA). 
dUPLC monitored at 280 nm. eUPLC 




2.4.4 Linear peptide synthesis: general procedure  
Linear peptide synthesis was performed as previously reported.3, 12 All peptides were 
assembled on a high load 2-chlorotrityl chloride resin (0.84 or 1.1 mmol/g, 85-1000 mg) by SPPS 
using Fmoc-protected amino acids according to standard procedures. The resin was first swollen 
with 10 mL of DCM (2 X 10 min). Peptides were synthesized on a manual multiple peptide 
synthesizer (“CHOIR”) constructed in house13 using 15 mL polypropylene syringes fitted with a 
polytetrafluoroethylene (PTFE) frits. Attachment of the first amino acid to the resin was performed 
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using a twofold excess of amino acid and fivefold excess of DIEA in DCM:N,N-
dimethylformamide (DMF) (4:1, 5 mL), which was allowed to agitate for 5-6 h. Any remaining 
active sites on the 2-chlorotrityl/chloride resin were deactivated by washing the resin with 15% 
MeOH and 5% DIEA in DCM (10 mL, 2 X 10 min).  Following removal of the Fmoc protecting 
group using 20% piperidine in DMF for 20 min, the resin was washed in DMF, DCM:DMF (1:1), 
and DCM  (10 mL, 5 X 30 sec each). 
The Fmoc-protected amino acids were then coupled using 2-fold excess and the coupling 
reagents PyBOB, 1-hydroxybenzotriazole (HOBt), and DIEA (2:2:5 relative to the resin 
substitution) in 10 mL DCM:DMF (1:1) for 2-4 h. None of the side chains were protected. 
Completion of the coupling reactions was indicated by the qualitative ninhydrin and/or chloranil 
test.14, 15 For peptide 1a, photodegradation was minimized by covering the vessel with aluminum 
foil during all reactions and during storage. 
 
2.4.5 Linear peptide cleavage 
All linear peptides were cleaved from the resin using 1% TFA in DCM (100 mL) that was 
bubbled through the resin in 5 mL portions for 2 min each. The resin was then washed with DCM 
(2 X 4 mL). All of the cleavage solution was drained into a round-bottom flask, and the DCM was 
then evaporated to dryness. The crude linear peptide was then triturated with diethyl ether (3 X 10 
mL), dried, re-dissolved in H2O:MeCN (approximately 3:1, 4-8 mL) and the solutions transferred 
to scintillation vials, frozen and lyophilized. Yields of crude linear peptide ranged from 46-220 
mg as white powders. The linear precursor of peptide 1 was protected from light using aluminum 
foil during cleavage, drying, and lyophilization. The linear peptides were analyzed by electrospray 
ionization mass spectrometry (ESI-MS) and ultra-performance liquid chromatography (UPLC, 
Table 2.4) as described below. 
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HPLC (tR (min)/% 
Purity)c 
[M+H]+ ESI-MS (m/z) 
Calculated Observed 
1aa 500b 153.2 60 6.03/80.6d 612.28 612.28 
2a 260b 56 44 6.30/>99d,e 601.32 601.32 
3a 332b 46.2 28 7.03/>99d,e 601.32 601.32 
4a 1000b 26.7 5 6.89/93.2e 601.32 601.32 
5a 436 245.3 88 6.92/94.1d 601.32 601.32 
6a 7a 500
b
 112.6 44 6.65/53.4, 7.01/46.6d 614.28 614.28 
7a 85 52 96 7.24/98.4e 614.28 614.28 
8a 400
b
 37 18 7.01/67.5d,e 614.28 614.28 
9a 400 223.9 83 6.94/89.0d 614.28 614.24 
10a 560 221.7 59 7.04/88.8d 614.28 614.28 
11a 400 228.9 85 6.95/>99d 614.28 614.28 
12a 358 136.7 57 6.28/96.5e 612.28 612.28 
13a 215 101.6 69 7.04/94.0d 626.30 626.30 
14a 215 124.4 84 6.94/97.0d 626.30 626.30 
15a 544 216 58 6.87/95.6e 626.30 626.27 
16a 400 219.9 80 6.83/>99d,e 626.30 626.26 
Resin loading was 1.1 mmol/g. aProtected from the light. b0.84 mmol/g resin loading. cUPLC 
analysis using a solvent system of 20-80% Solvent B over 14 min (Solvent A= H2O; Solvent B= 
MeCN, both containing 0.1% TFA). dUPLC monitored at 280 nm. eUPLC monitored at 214 nm. 
 
2.4.6 Cyclization of linear tetrapeptides  
Cyclization procedures were modified from previously reported methods.3, 12 Half of the 
crude linear peptide (1 equiv for this purpose) in DMF (10-20 mL) was added dropwise at a rate 
of 1.2 mL/h (using a KD Scientific single infusion syringe pump) to a dilute solution of HATU 
(1.5 equiv) and DIEA (8 equiv) in DMF. Additional HATU (1.5 equiv) and DIEA (8 equiv) was 
then added to the reaction in one portion, and the second half of the linear peptide (1 equiv) in 
DMF (10-20 mL) was added dropwise at a rate of 1.2 mL/h, as described above. The linear 
precursors 7a, 9a-12a were delivered in one portion (20 mL DMF) at 0.5 mL/h. The final 
concentrations after additions of the linear peptide, HATU, and DIEA in DMF were 1, 1.5, and 8 
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mM, respectively. The total reaction times were 37.5-70.5 h. Peptide 1 was cyclized under argon 
gas and protected from light with aluminum foil. 
The solvent was evaporated under reduced pressure at 37 °C, the resulting residue was 
dissolved in EtOAc (100 mL), and the organic phase washed sequentially with 1 N citric acid, 
saturated NaHCO3 solution, and brine (3 X each). The organic phase was dried over anhydrous 
MgSO4, and the filtrate evaporated under reduced pressure to give the crude macrocyclic 
tetrapeptide, which was purified by silica gel chromatography with gradients of EtOAc in hexanes 
or MeOH in DCM using a Teledyne Combi Flash Rf system and monitoring at 254 and 280 nm. 
Peptides 1, 5-6, and 9-16 underwent an additional purification step by selective precipitation with 
EtOAc (peptide 1), 25% MeCN in H2O (peptides 5-6, 9-11, and 13-16), or 100% MeCN (peptide 
12). The peptide was then dried and re-dissolved in H2O:MeCN (approximately 2:1, 4-8 mL) and 
the solutions transferred to scintillation vials, frozen and lyophilized. Yields of pure cyclic peptide 
(≥97% pure) ranged from 1-110 mg (4-57% yield) as white powders. Specific reaction conditions, 

























1 120b 4.9/20c 67.5 
0-5% MeOH  
in DCM 
EtOAc 21.1 18 
2 50 4.3/10c 37.5 
40-100% EtoAc 
in hexanes 
- 16.6 34 
3 40 3.3/10c 37.5 
30-100% EtoAc 
in hexanes 
- 20 52 
4 24 2.0/10c 47 
35-100% EtoAc 
in hexanes 
- 0.93 4 
5 240 10/20c 48 














7 50 4.1/20d 68.5 
0-5% MeOH  
in DCM 
- 1.3 3 
8 35 1.4/20c 47 
35-100% EtoAc 
in hexanes 
- 4.1 12 
9 200 16/20d 45 











11 200 16//20d 64 





12 130 11/20d 68.5 
0-10% MeOH  
in DCM 
MeCN 5.4 4 
13 100 4.0/20c 48 





14 100 4.0/20c 48 





15 200 8.0/20c 48 
0-5% MeOH 




16 200 8.0/20c 48 





aThe final concentrations of linear peptide, HATU, and DIEA in DMF were 1, 1.5, and 8.0 mM, 
respectively; the reactions were performed at room temperature. bThe reaction was performed 
under argon gas and protected from light. cThe linear peptide was delivered in two portions at 1.2 
mL/h. dThe linear peptide was delivered in one portion at 0.5 mL/h.  
 
2.4.7 HPLC, UPLC, and MS analysis 
Mass spectra of the protected amino acids, the macrocyclic tetrapeptides, and their linear 
precursors were obtained on a Waters LCT Premier ESI time of flight mass spectrometer.  
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The purity of Fmoc-protected tryptophan analogs and the linear peptides was verified on a 
Waters Acquity H-class UPLC chromatograph equipped with Quaternary Solvent Manager, 
Sample Manager FTN and TUV Detector. An Acquity UPLC BEH C18 column (1.7 μ, 130 Å, 2.1 
x 50 mm) equipped with an Acquity UPLC BEH C18 VanGuard pre-column (1.7 μ, 130 Å, 2.1 x 
5 mm) was used with a flow rate of 0.2 mL/min. A gradient of 40-80% MeCN in H2O over 14 min 
was used for the protected tryptophan analogs (Table 2.3) and 20-80% MeCN in H2O over 14 min 
was used for the linear peptides (Table 2.4). Solutions of peptides or amino acids were injected at 
a volume of 0.5-10 μL and detected at 214 and 280 nm. Chromatographic data were acquired and 
analyzed using Waters Empower 3 software. Spectral data can be found in Table 2.3 for the Fmoc-
protected amino acids and in Table 2.4 for the linear peptide precursors. 
 The Fmoc-protected Phe analogs and the macrocyclic tetrapeptides were analyzed using 
an Agilent 1200 series liquid chromatograph system equipped with a multiple wavelength UV-Vis 
detector. HPLC analyses were performed on a Vydac 218TP C18 column (5 µ, 4.6 x 50 mm) at a 
flow rate of 1 mL/min. The Fmoc-protected Phe analogs were analyzed using a solvent system of 
30-70% Solvent B over 40 min (Solvent A= H2O; Solvent B= MeCN, both containing 0.1% TFA). 
The macrocyclic peptides were analyzed using two different solvent systems: system 1: 15-55% 
MeCN containing 0.1% TFA over 40 min, system 2: 30-70% MeOH over 40 min, with detection 






Table 2.6: Analytical data for the cyclic peptides 
Peptide HPLC (tR (min)/% Purity) [M+Na]
+ ESI-MS (m/z) 
System 1c System 2d Calculated Observed 
1 12.46/>99 9.93/>99 616.25 616.26 
2 18.78/>99 18.74/>99 605.29 605.29 
3 26.09/>99 27.54/>99 605.29 605.29 
4 18.82/97.9 19.56/>99 605.29 605.29 
5 18.70/>99 19.11/>99 605.29 605.29 
6 20.17/>99 20.25/>99 618.25 618.25 
7a 27.69/97.5 29.7/94.2 618.25 618.25 
7b 27.57/>99 30.23/97.6 618.25 618.25 
8 20.16/97.6 20.88/>99 618.25 618.25 
9 19.81/>99 20.63/>99 618.25 618.25 
10 19.86/98.4 20.86/>99 618.25 618.25 
11 19.88/>99 20.87/>99 618.25 618.25 
12 15.30/>99 13.39/>99 616.25 616.26 
13 19.46/>99 20.65/>99 630.27 630.27 
14 19.25/99.0 20.29/98.9 630.27 630.27 
15 18.90/>99 19.98/>99 630.27 630.27 
16 18.77/>99 19.96/>99 630.27 630.27 
aCyclized from D/L-Trp(5-F) mixture of linear precursors. aCyclized from pure D-Trp(5-F) 
linear precursor. cSystem 1: 15-55% Solvent B over 40 min (Solvent A= H2O; Solvent B= 
MeCN, both containing 0.1% TFA), dSystem 2: 30-70% Solvent B over 40 min (Solvent A= 
H2O; Solvent B= MeOH, both containing 0.1% TFA), flow rate 1.0 mL/min. 
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Chapter III: CJ-15,208 and [D-Trp]CJ-15,208: Their Permeability Across Biological 
Barriers and Interaction with P-glycoprotein 
 
3.1 Introduction 
We are interested in orally bioavailable and centrally acting peptidic ligands for kappa 
opioid receptors (KOPr) as potential treatments for drug abuse and pain. For background on our 
two lead compounds, CJ-15,208 and [D-Trp]CJ-15,208, their activities and metabolic stabilities 
please see section 1.3. While these compounds have shown central activity after oral delivery in 
mice, this activity requires high doses.1, 2 We would like to identify the factors limiting central 
exposure of these peptides in order to design analogs with greater membrane permeability and 
CNS levels.  
Previous studies in our laboratory using Caco-2 cell monolayers indicated that both CJ-
15,208 and [D-Trp]CJ-15,208 are permeable across biological barriers, with Papp (apparent 
permeability coefficient) values of 3.2 x 10-6 cm/sec (A to B) and 18.9 x 10-6 cm/sec (B to A) for 
the L-Trp isomer and 25.5 x 10-6 cm/sec (A to B) and 22.7 x 10-6 cm/sec (B to A) for the D-Trp 
isomer.3 CJ-15,208 appeared to be effluxed, with a Papp ratio ((B to A)/(A to B)) of 5.9, but these 
studies did not identify efflux proteins interacting with CJ-15,208. It was hypothesized that P-
glycoprotein (P-gp) may be involved in the observed efflux, as this protein interacts with many 
hydrophobic substrates and is present at the intestinal barrier and blood-brain barrier (BBB).4 For 
an overview of the BBB, prominent BBB efflux proteins, and in vitro models of the BBB see 
section 1.4. 
As a model of the intestinal barrier, Caco-2 cells have the advantage of being derived from 
a human intestinal cancer and of expressing a variety of efflux proteins.5 However, Caco-2 cells 
require 21 days of development, and slow growth increases the risk of contamination and of the 
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monolayer becoming damaged. Madin-Darby canine kidney (MDCK) cells have been used as a 
faster alternative to Caco-2 cells for modeling the intestinal barrier.6 While MDCK cells are 
derived from canine kidney cells and do not express efflux proteins at the same basal levels that 
are observed in Caco-2 cells,7 they develop in 6 days and can be transfected to express human 
efflux proteins such as P-gp (gene MDR1). Additionally, while MDCK cells are models of the 
intestinal barrier, when they are transfected with efflux proteins present at the BBB, they can be 
used to predict permeability across the BBB.8, 9  These cell lines have been successfully used to 
study cyclic opioid peptides.10 
In this study, we used wild type MDCK cells (MDCK-WT) and MDCK cells transfected 
with the multidrug resistant gene 1 (MDR1) expressing human P-gp to determine the interactions 
of CJ-15,208 and [D-Trp]CJ-15,208 with P-gp. The two experiments performed with these cells 
were the rhodamine 123 (Rh 123) efflux assay, which uses the fluorescent P-gp efflux substrate 
Rh 123 to determine whether the peptides can inhibit P-gp efflux, and transwell transport across 
MDCK cell monolayers to determine whether the peptides are effluxed by P-gp.  
 
3.2 Results and Discussion 
3.2.1 Rhodamine 123 efflux studies 
The MDCK-MDR1 cells were seeded on 24 wells plates, and monolayers were cultured 
for 6 days. On the 6th day the monolayer integrity was assessed visually, and then the monolayers 
preincubated with the vehicles, peptides, or the P-gp inhibitor verapamil for 30 min at 37 oC. Rh 
123 was then added, and the monolayers incubated for another 60 min. The monolayers were then 
washed and lysed, and the fluorescence of Rh 123 in the cell lysate measured. The protein 
concentration of the lysate was measured using the bicinchoninic acid (BCA) assay, and the 
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fluorescence normalized for protein concentration to calculate the relative fluorescence units 
(RFU).  
Vehicles to solubilize the analogs in Hank’s balanced salt solution (HBSS) were chosen in 
previous Caco-2 studies.3 CJ-15,208 and [D-Trp]CJ-15,208 were solubilized in 0.25% 
dimethylsulfoxide (DMSO) + N,N-dimethylacetamide (DMA) in HBSS (vehicle 1) or 0.25% 
DMSO +  2.25% N-methylpyrrolidone (NMP) in HBSS (vehicle 2), respectively. While these 
vehicles were successfully used in the Caco-2 assays, vehicle 2 appeared to affect the uptake of 
Rh 123 in unpredictable ways in initial studies (protein concentration was not measured during 
these initial studies). This vehicle consistently increased fluorescence without peptide, but when 
[D-Trp]CJ-15,208 was added, the fluorescence was decreased back to control levels (Figure 3.1). 
[D-Trp]CJ-15,208 was observed to form visible peptide aggregates in vehicle 1, and these 
aggregates appeared to potently inhibit P-gp efflux (Figure 3.1). The vehicle selected to solubilize 
[D-Trp]CJ-15,208 was 1% DMSO in HBSS, which did not appear to significantly affect Rh 123 
uptake (Figure 3.1) and did not result in visible peptide aggregates. However, subsequent studies 
showed variability in the fluorescence in controls containing 1% DMSO in HBSS (data not 





Figure 3.1: Initial data on the effect of [D-Trp]CJ-15,208 vehicles on the efflux of Rh 123 in 
MDCK-MDR1 cell monolayers (n = 2). 
 
3.2.1.1 CJ-15,208 inhibition of Rh 123 efflux 
CJ-15,208 was soluble in vehicle 1, and therefore this vehicle was used in studies of the 
effect of this peptide on Rh 123 efflux. A statistically significant increase in Rh 123 uptake was 
observed at 40 μM CJ-15,208 (Figure 3.2), suggesting that CJ-15,208 is an inhibitor of P-gp. The 
lower P-gp inhibition at 50 μM may be due to poor aqueous solubility of the compound.  
 
 
Figure 3.2: Initial data on the effect of CJ-15,208 on the efflux of Rh 123 in MDCK-MDR1 cell 
monolayers (n = 1). All compounds are in Vehicle 1. *Statistically different (p < 0.05) from 



































[D-Trp]CJ-15,208 (50 µM) 




3.2.2 Permeability studies 
The transport of CJ-15,208 and [D-Trp]CJ-15,208 across MDCK cell monolayers was 
determined using quantification by UPLC-MS/MS. The MDCK-WT and MDCK-MDR1 cells 
were seeded on polycarbonate filters, and monolayers were cultured for 6 days. On the 6th day the 
monolayer integrity was assessed by measuring the transepithelial electrical resistance (TEER) 
and lucifer yellow (LY) transport (both Papp values and percent permeability over 1 h). TEER 
values of  >200 Ω/cm2 and a Papp values for LY of ≤0.5 x 10
-5 cm/sec were observed for MDCK-
WT, which generally met the criteria used to indicate formation of tight junctions11 and were 
consistent with previously reported values.12 In these studies the MDCK-MDR1 cell mono-layers 
did not meet these criteria;11 lower TEER values for MDCK-MDR1 cell monolayers have also 
been reported by others.13 Therefore the criteria for MDCK-MDR1 cell monolayers in these 
studies were TEER values of >140 Ω/cm2  and a Papp values for LY of  ≤1.5 x 10
-5 cm/sec without 
GF-120918 (elacridar, 5 µM) and ≤2.5 x 10-5 cm/sec with GF-120918.  
CJ-15,208 and [D-Trp]CJ-15,208 were solubilized in the same vehicles used in the Rh 123 
efflux studies, namely in vehicle 1 and 1% DMSO in HBSS, respectively, at a concentration of 50 
M. The transport experiments were conducted six days after seeding. For experiments utilizing 
the P-gp inhibitor GF-120918 (5 M), the MDCK-MDR1 cell monolayers were incubated with 
the P-gp inhibitor for 20 min before the peptide was added.14, 15 The transwells containing MDCK-
WT or MDCK-MDR1 monolayers were incubated with the peptides in their respective vehicles 
for 2 h with samples collected for transport in both the apical to basolateral (A-B) and basolateral 
to apical (B-A) directions, followed by examining transport of LY in the A-B direction. 
Concentrations of CJ-15,208 and [D-Trp]CJ-15,208 were quantified using liquid 
chromatography electrospray ionization tandem mass spectroscopy (LC-ESI-MS/MS) in positive 
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ion mode coupled to reversed phase ultra-high performance liquid chromatography (RP-UPLC). 
Following fragmentation, multiple reaction monitoring (MRM) was used to quantify the peptides. 
 
Table 3.1: Results obtained from MDCK-WT and MDCK-MDR1 monolayer permeability 





Peptide transport Post-peptide LY transport 
Mass balance (% ) 
± SEM Papp cm/sec (x 10
-5) 
± SEM 
Papp cm/sec (x 10-5) ± SEM 
(% permeability ± SEM) 
A-B B-A 
Peptide (A-B) Peptide (B-A) 
A-B B-A 





 1.2 ± 0.2 3.4 ± 0.4 
1.2 ± 0.2 
(4.1 ± 0.6) 
1.3 ± 0.1 
(4.6 ± 0.1) 





1.8 ± 0.2 3.5 ± 0.4 
0.68 ± 0.08 
(2.8 ± 0.5) 
0.89 ± 0.07 
(4.9 ± 1.0) 






1.6 ± 0.3 1.7 ± 0.2 
1.5 ± 0.1 
(5.0 ± 0.1)b 
1.9 ± 0.1 
(7.4 ± 0.5)b 








1.5 ± 0.1 
0.16 ± 0.01 
(0.8 ± 0.1) 
0.12 ± 0.05 
(0.7 ± 0.1) 





2.7 ± 0.1 2.9 ± 0.2 
0.22 ± 0.03 
(1.0 ± 0.2) 
0.23 ± 0.02 
(1.3 ± 0.3) 
88 ± 8 85 ± 6 
Percent permeability calculated from cumulative fraction of LY transported at 60 min. aResults 
presented are mean ± SEM from two or three experiments. bResults presented are mean ± SEM 
from a single experiment. 
 
 
3.2.2.1 Permeabilities across MDCK-MDR1 cell monolayers 
Permeability of CJ-15,208 across MDCK-MDR1 cell monolayers 
CJ-15,208 was permeable across MDCK-MDR1 monolayers. It showed Papp values of 1.2 
± 0.2 x 10-5 cm/sec in the A-B direction and 3.4 ± 0.4 x 10-5 cm/sec in the B-A direction (Figure 
3.3 and Table 3.1). The value for B-A transport was almost 3 times the value for A-B transport, 
which suggests that CJ-15,208 could be a substrate for an efflux transporter. To verify whether 
this was due to P-gp, additional transport studies were conducted in the presence of the P-gp 
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inhibitor GF-120918. The permeability of CJ-15,208 in the presence of GF-120918 slightly 
increased in the A-B direction (1.6 ± 0.3 x 10-5 cm/sec) and decreased by two-fold in the B-A 
direction (1.7 ± 0.2 x 10-5 cm/sec, Figure 3.4 and Table 3.1). The Papp ratio was about 1 in the 
inhibitor studies, suggesting that GF-120918 was able to inhibit efflux and that CJ-15,208 is likely 
effluxed to some degree by P-gp. 
 
 
Figure 3.3: MDCK-MDR1 monolayer permeability of CJ-15,208 (n = 3). Papp = slope x volume 
of receiver chamber (cm3)/area of the filter (cm2) x 60 (sec), where the volume of receiver chamber 








































(B-A) 3.4 ± 0.4 x10-
5 cm/sec





Figure 3.4: MDCK-MDR1 monolayer permeability of CJ-15,208 + GF-120918 (n = 2). Papp values 
were calculated using the formula shown in the legend to Figure 3.3. 
 
The MDCK-MDR1 monolayers showed relatively high permeability of a control (LY) in 
these experiments with CJ-15,208. Monolayers with and without GF-120918 appeared relatively 
consistent between wells used for transportation in the A-B and B-A directions, both showing 
TEER values of >140 Ω/cm2 for all monolayers and an average LY transport of 1.2 ± 0.2 x 10-5 
cm/sec (4.1 ± 0.6% permeability over 1 hour) in the wells used to study A-B transport and 1.3 x ± 
0.1 10-5 cm/sec (4.6 ± 0.1% permeability) in the wells used to study B-A transport without GF-
120918 (Figure 3.10 and Table 3.1) and an average LY transport of 1.5 x ± 0.1 10-5 cm/sec (5.0 ± 
0.1% permeability) in the wells used to study A-B transport and 1.9 ± 0.1 x 10-5 cm/sec (7.4 ± 
0.5% permeability) in the wells used to study B-A transport with GF-120918 present (Table 3.1). 
However, these cell monolayers showed lower TEER values and greater LY permeability than 
those of the MDCK-WT cell monolayers, suggesting that they did not form tight junctions as 
efficiently. Similar results have been reported by others for MDCK-MDR1 cell monolayers.13 The 






































(B-A) 1.7 ± 0.2 x10-
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A permeability studies for CJ-15,208 without GF-120918 and 77 ± 7% for the A-B permeability 
studies and 70 ± 8% for B-A permeability studies for CJ-15,208 with GF-120918 (Table 3.1). 
Permeability of [D-Trp]CJ-15,208 across MDCK-MDR1 cell monolayers 
[D-Trp]CJ-15,208 was also permeable across MDCK-MDR1 monolayers. It showed a Papp 
value of 1.8 ± 0.2 x 10-5 cm/sec in the A-B direction and 3.5 ± 0.4 x 10-5 cm/sec in the B-A direction 
(Figure 3.5 and Table 3.1). The value for B-A transport was almost twice the value for A-B 
transport which suggests that [D-Trp]CJ-15,208 could be a substrate for an efflux transporter, 




Figure 3.5: MDCK-MDR1 monolayer permeability of [D-Trp]CJ-15,208 (n = 1). Papp values were 
calculated using the formula shown in the legend to Figure 3.3. 
 
The MDCK-MDR1 monolayers also had relatively high permeability to a control in 
experiments with [D-Trp]CJ-15,208. The monolayers appeared relatively consistent between wells 










































(B-A) 3.5 ± 0.4 x10-
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and average LY of 0.68 ± 0.08 x 10-5 cm/sec (2.8 ± 0.5% permeability) in the wells used to study 
A-B transport and 0.89 ± 0.07 x 10-5 cm/sec (4.9 ± 1.0% permeability) in the wells used to study 
B-A transport (Figure 3.13 and Table 3.1). These are about half of the LY permeabilities observed 
for the CJ-15,208 studies using MDCK-MDR1 cells. The mass balance (± SEM) was 73 ± 5% for 
the A-B permeability studies and 81 ± 5% for B-A permeability studies for the D-Trp isomer (Table 
3.1). 
 
3.2.2.2 Permeabilities across MDCK-WT cell monolayers 
Permeability of CJ-15,208 across MDCK-WT cell monolayers 
In this study, MDCK-WT cells also served as a control for efflux by human P-gp. CJ-
15,208 was permeable across MDCK-WT monolayers. It showed a Papp value of 0.60 ± 0.05 x 10
-
5 cm/sec in the A-B direction and 1.5 ± 0.1 x 10-5 cm/sec in the B-A direction (Figure 3.6 and 
Table 3.1). The value for B-A transport was about 2.5 times the value for A-B transport which 




Figure 3.6: MDCK-WT monolayer permeability of CJ-15,208 (n = 2). Papp values were calculated 
using the formula shown in the legend to Figure 3.3. 
 
The MDCK-MDR1 and MDCK-WT cells were examined for P-gp expression using 
western blot analysis with an antibody with affinity for human and canine P-gp, and no P-gp 
expression was detected in the MDCK-WT cells (Figures 3.7 and 3.8). However, efflux by canine 
P-gp in MDCK-WT cells was not examined using inhibitors in the these studies, and canine P-gp 
has been detected in MDCK-WT cells using a higher concentration of the antibody.16 Canine forms 
of MRP efflux proteins has also been detected in MDCK cells,16, 17 and one study suggests that 
they can be more highly expressed in MDCK-MDR1 cells than wild type cells.16 It has been shown 
that transfection with the human MDR1 gene can affect the expression of endogenous MDCK 
transport proteins,16 so another unidentified efflux protein may be effecting these results. Inhibitor 
studies18 are required to determine what efflux proteins may be involved in the observed efflux in 
the WT cells. Since the Papp ratios of CJ-15,208 across MDCK-MDR1 cells and MDCK-WT cells 






































(B-A) 1.5 ± 0.1 x10-
5 cm/sec





Figure 3.7: Western blot of P-gp in MDCK-WT and MDR1 cells following 6 days in culture. 
 
 
Figure 3.8: Ratio of P-glycoprotein/β-actin in MDCK-WT and MDCK-MDR1 cells as measured 
by Western blot analysis. 
 
The MDCK-WT monolayers appeared consistent between wells used for transportation in 
the A-B and B-A directions, both showing TEER values of >200 Ω/cm2 and an average LY of 0.22 
± 0.03 x 10-5 cm/sec (0.8 ± 0.1% permeability) in the wells used to study A-B transport and 0.23 ± 
0.02 x 10-5 cm/sec (0.7 ± 0.1% permeability) in the wells used to study B-A transport (Table 3.1). 
The mass balance (± SEM) was 95 ± 5% for the A-B permeability studies and 92 ± 3% for B-A 































Permeability of [D-Trp]CJ-15,208 across MDCK-WT cell monolayers 
In MDCK-WT monolayers, [D-Trp]CJ-15,208 showed a permeability of 2.7± 0.1 x 10-5 
cm/sec in the A-B direction and 2.9 ± 0.2 x 10-5 cm/sec in the B-A direction (Figure 3.9 and Table 
3.1). The value for B-A transport was equal to the value for A-B transport which suggests that [D-
Trp]CJ-15,208 is a not substrate for an endogenous efflux transporter in these cells. The MDCK-
WT monolayers appeared consistent between wells used for transportation in the A-B and B-A 
directions, both showing TEER values of >200 Ω/cm2 and an average LY of 0.22 ± 0.03 x 10-5 
cm/sec (1.0 ± 0.2% permeability) in the wells used to study A-B transport and 0.23 ± 0.02 x 10-5 
cm/sec (1.3 ± 0.3% permeability) in the wells used to study B-A transport (Table 3.1). The mass 
balance (± SEM) was 88 ± 8% for the A-B permeability studies and 85 ± 6% for B-A permeability 
studies for the D-Trp isomer (Table 3.1). 
 
 
Figure 3.9: MDCK-WT monolayer permeability of [D-Trp]CJ-15,208 (n = 2). Papp values were 
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3.2.3 Potential for active transport 
A short lag of about 10 min was detected between the time when either peptide was added 
to the monolayer and when transport was observed in both MDCK-WT and MDCK-MDRI studies 
(Figures 3.3-3.6 and 3.9), suggesting that these peptides may be actively transported. A similar 10 
min lag time was observed across Caco-2 cells.3 Kinetic studies with varying temperatures could 
be conducted to examine this hypothesis.19  
 
3.3 Conclusions and future directions  
These preliminary results suggest that CJ-15,208 interacts with and is effluxed by efflux 
protein(s), but the similar Papp ratios observed across both MDCK-MDR1 and MDCK-WT cell 
monolayers make it unclear which efflux proteins are involved. The efflux is eliminated in the 
presence of GF-120918, however this inhibitor has been shown to eliminate efflux by endogenous 
canine efflux proteins in MDCK-WT cells as well.20 Further, GF-120918, which is also a potent 
inhibitor of the breast cancer related protein (BCRP)21 as well as MDR1, was not used in these 
MDCK-WT transport studies. It is possible that CJ-15,208 may be effluxed by other proteins 
expressed in MDCK-WT cells, including canine isoforms of P-gp17 or MRP2,16 suggesting further 
studies using different inhibitors. While P-gp was not detected in the MDCK-WT cells using 
Western blot analysis, other studies have detected P-gp in MDCK-WT cells using a higher 
concentration of P-gp antibody.16 There was no evidence of efflux of [D-Trp]CJ-15,208 across 
MDCK-WT cell monolayers, but a Papp ratio of 2 in a preliminary study suggested possible efflux 
across MDCK-MDR1 cells. Additional studies are required to confirm these results, and inhibitor 
studies22 can be used to determine what efflux proteins may be involved. Lag times in the transport 
of both of these peptides suggest the possibility of active transport, possible via endocytosis.23 
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Permeability studies of [D-Trp]CJ-15,208 across MDCK-MDR1 cell monolayers should 
be repeated, and GF-120918 could be used to determine whether any observed efflux is due to 
canine P-gp in MDCK-WT cells (BCRP has been reported to be low in these cells16). Additionally, 
these experiments could be repeated with lower concentrations (< 5 µM) of either peptide. Efflux 
proteins have been shown to be saturable,24 and 50 µM may be too high a concentration to observe 
efflux by proteins with lower expression or activity in these cell lines. Carrier-mediated transport 
could also be assessed using variable temperature studies.24 
 
3.4 Experimental section 
3.4.1 Materials and instrumentation 
Dulbecco’s modified Eagle’s medium (DMEM) was obtained from Gibco (Grand Island, 
NY), and fetal bovine serum (FBS) was obtained from Atlanta Biologics (Lawrenceville, GA). 
Non-essential amino acids, penicillin and streptomycin were purchased from Cellgro (Manassas, 
VA). HBSS, pH 7.4, colchicine, lucifer yellow, Elacridar (GF-120918), protein standard, 
monoclonal anti-β-actin antibody, Tris base, ethylenediaminetetraacetic (EDTA), ethylene 
glycol tetraacetic acid (EGTA), sodium dodecyl sulfate (SDS), sodium chloride (NaCl), sodium 
deoxycholate, phenylmethanesulfonyl fluoride (PMSF), DMA, TWEEN-20, and TritonX100 were 
purchased from Sigma-Aldrich (St. Louis, MO), and polycarbonate transwell filters and 
polystyrene plates were obtained from Costar (Corning, NY). C219 mouse monoclonal antibody 
A to P-glycoprotein was purchased from Covance (Princeton, NJ). Horseradish peroxidase-
conjugated anti-mouse secondary antibody was purchased from Jackson ImmunoResearch Inc. 
(West Grove, PA). Dimethyl sulfoxide (DMSO, molecular biology grade), sodium pyruvate, 
sodium bicarbonate, HEPES, glycine, (±)-verapamil hydrochloride, a BCA protein assay reagent 
kit, and protease inhibitor cocktail (PI-78441) were purchased from Thermo Fisher Scientific 
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(Waltham, MA). Criterion precast gels, 4-20% Tris-HCl, 1.0 mm, 1X Tris-Glycine SDS running 
buffer, 4x Laemmli sample buffer, protein standard (161-0374), and SuperSignal West Pico 
Chemiluminescence substrate were purchased from Bio-Rad Laboratories, Inc. (Hercules, CA). 
Immoblion-P polyvinylidene difluoride (PVDF), 0.45um pore, membranes were purchased from 
Millipore (Billerica, MA). Rhodamine 123 was purchased from MP Biomedicals, LLC (Santa Ana, 
CA). CJ-14,280 and [D-Trp]CJ-15,208 were synthesized and purified by Dr. Sanjeewa N. 
Senadheera.25 
 A SpectraMax M5 microplate fluorometer (Molecular Devices, Sunnyvale) was used for 
analysis of LY transport. A Synergy HT microplate reader (BioTek, Winooski, VT) was used for 
analysis of Rh 123 efflux and protein concentration. LC-MS/MS analysis of peptide concentration 
in the peptide transport study was performed on an Acquity Ultra Performance liquid 
chromatography (UPLC) system coupled to a Quattro mass spectrometer (Waters, Milford) in the 
University of Kansas Mass Spectroscopy Laboratory. 
 
3.4.2 Cell culture 
MDCK-WT and MDCK-MDR1 cells (obtained from Dr. P. Borst, the Netherlands Cancer 
Institute, Amsterdam, passage 62-70) were grown in a humidified incubator at 37 oC under 5% 
CO2 in air in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% heat inactivated 
FBS, 0.1 mM nonessential amino acids, 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL 
streptomycin. MDCK-MDR1 cells were grown in the presence of 80 ng/mL colchicine. MDCK 
cells were seeded on polycarbonate transwells (0.4 µM pore size, 12 mm diameter, Costar #3401) 
or 24 well plates at a density of 50,000 cells/cm2 and grown for 6 days. Cell culture media was 





Western blot analysis was performed to detect P-gp protein expression. Six days after 
seeding, the cells were trypsinized by the addition of 1.5 mL trypsin which was aspirated out after 
ten seconds, and the cells then incubated at 37oC for 5 min. The cells were then resuspended in 
ice-cold DPBS and pelleted by centrifugation (1,500 RPM for 10 min). The pellets were lysed in 
RIPA buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% 
sodium deoxycholate, 0.1% SDS, and 140 mM NaCl; 1 mM PMSF was added immediately before 
use), incubated at 4 oC for 20 min with occasional vortexing, transferred to eppendorf tubes, and 
centrifuged at 1,320 RPM for 15 min. The protein concentration of the supernatant was determined 
using a BCA protein assay reagent kit. To insure detection of any low-level expression of P-gp in 
MDCK-WT cells, 50-150 μg of total cellular protein were used for Western blotting. The samples 
and a protein standard were diluted with 4x Laemmli sample buffer (277.8 mM Tris-HCl, pH 6.8, 
4.4% lithium dodecyl sulfate (LDS), 44.4% (w/v) glycerol, and 0.02% bromophenol blue). The 
samples were then analyzed by electrophoresis on a Criterion precast gel, 4-20% Tris-HCl, 1.0 
mm, with a 1X Tris-glycine SDS running buffer. The proteins were transferred onto Immoblion-
PVDF 0.45 um pore membranes in transfer buffer (48 mM Tris, 39 mM glycine pH 9.2, and 1.3 
mM SDS) using a  Trans-Blot SD semi-dry transfer cell (Bio-Rad Laboratories, Inc., Hercules, 
CA) at 10V+ overnight. 
After transfer membranes were blocked for one hour at room temperature in blocking 
solution [3% bovine serum albumin (BSA) and 0.1% TWEEN-20 in Tris-buffered saline (TBS, 
0.025 M Tris, pH 7.5, 0.15 M NaCl)]. Membranes were then incubated overnight at 4 oC with 
C219 (anti-P-gp) mouse monoclonal antibody A (1:1,000 dilution in 15 mL blocking solution) or 
monoclonal anti-β-actin antibody produced in mouse (1:3,000 dilution in 15 mL blocking 
solution). The membranes were then washed with 0.3% Tween-20 in TBS 3 times for 20 min each. 
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Next, membranes were incubated for 45 min at room temperature with secondary antibody, 
horseradish peroxidase-conjugated anti-mouse antibody (1:5,000 dilution in 15 mL blocking 
solution). The membranes were washed again as previously described. Chemiluminescence signals 
of protein bands were detected using SuperSignal West Pico Chemiluminescence substrate.  The 
intensity of the chemiluminescence signals for the proteins were determined using a Kodak Image 
Station 4000R imager, and protein band intensity was quantified by ImageJ software (NIH, 
Bethesda, MD). 
 
3.4.4 Rhodamine 123 efflux experiments 
MDCK–MDR1 cell monolayers were washed twice with 500 μL HBSS, and pre-incubated 
with CJ-15,208 (in 2.25% DMA and 0.25% DMSO in HBSS, vehicle 1) or [D-Trp]CJ-15,208 (in 
1% DMSO in HBSS), 0-50 µM, for 30 min at 37oC. Verapamil (600 µM) in vehicle 1 was used as 
a positive control. The monolayers were then incubated with 5 µM rhodamine 123 at 37 oC for 60 
min, washed with ice-cold phosphate-buffered saline (PBS, 2 x 500 μL) and lysed with 200 μL 
ice-cold 1% Triton X100 in PBS. Fluorescence (excitation 497 nm, emission 526 nm) was 
measured and protein concentration in the cell lysate was determined using the BCA assay. 
Relative fluorescence units (RFU) were calculated as follows: 
RFU = (Fluorescence comp – Fluorescence background)/protein concentration (mg/mL) 
 
3.4.5 Standard curves of the low permeability standard lucifer yellow (LY) 
The standard curve of LY was obtained in HBSS ranging over a range of concentrations 
(1-100 µM) and displayed linearity (r2 = 0.9998, Figure 3.10). The solutions of LY (200 L) were 
74 
 




Figure 3.10: Representative standard curve for LY 
 
3.4.6 Transport experiments 
The integrity of the cell monolayers was examined by measuring TEER values and the 
transport of the low paracellular permeability standard LY. The TEER values were corrected by 
subtracting background values for the filters. The criteria to use the cell monolayers for transport 
studies for MDCK-WT monolayers were TEER values of  >200 Ω/cm2 and a Papp values for LY of 
≤0.5 x 10-5 cm/sec.11, 12  The criteria to use the cell monolayers for transport studies for MDCK-
MDR1 monolayers were TEER values of  >140 Ω/cm2 and a Papp values for LY of ≤1.5 x 10
-5 
cm/sec (MDCK-MDR1), and ≤2.5 x 10-5 cm/sec (MDCK-MDR1 + GF-120918).13 The filters 
containing cell monolayers were washed twice with HBSS, pH 7.4, at 37 oC. For assessment of 
monolayer integrity of the cells, HBSS on the apical side was replaced with LY (0.5 mL of 100 
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M solution in HBSS). The LY transport to evaluate cell monolayer integrity was performed 
during the 3rd h after the initial 2 h peptide transport experiment. The experiment was performed 
in duplicate or triplicate for 60 min with aliquots (200 L) taken at 15, 30, 45, and 60 min from 
the basolateral side. At every time point an aliquot was removed it was replaced by an equal 
amount of HBSS to maintain constant volume. The samples were analyzed using a 96 well 
fluorescence plate reader (see Materials). Examples of LY transport in MDCK-MDR1 and 
MDCK-WT cells can be seen in Figures 3.11 and 3.12, respectively. 
 
 
Figure 3.11: Example of post peptide LY transport through MDCK-MDR1 monolayers.  Wells 
were treated with CJ-15,208 (L-Trp peptide) in vehicle 1 or [D-Trp]CJ-15,208 (D-Trp peptide) in 
1% DMSO in HBSS for the initial 2 h, and LY transport was then carried out in the wells during 














































Figure 3.12: Example of post peptide LY transport through MDCK-WT monolayers.  Wells were 
treated with CJ-15,208 (L-Trp peptide) in vehicle 1 or [D-Trp]CJ-15,208 (D-Trp peptide) in 1% 
DMSO in HBSS for the initial 2 h, and LY transport was then carried out in the wells during the 
3rd h. 
 
Transport experiments for the peptides were performed similarly to the procedure 
described above for LY. For experiments utilizing the P-gp inhibitor GF-120918, the MDCK-
MDR1 cell monolayers were incubated with the P-gp inhibitor (5 M) in the appropriate vehicle 
in the donor side for 20 min before the peptides were added. Transport in the A-B and B-A 
directions was performed in duplicate or triplicate and monitored by the collection of aliquots at 
10, 20, 30, 60, 90, and 120 min. At every time point an aliquot was removed it was replaced by an 
equal amount of HBSS to maintain constant volume. Early time points were taken to monitor any 
initial lag in the transport of the two peptides. The working concentration used for both CJ-15,208 
and [D-Trp]CJ-15,208 was 50 µM in vehicle 1 and 1% DMSO in HBSS, respectively. Aliquots of 
the donor compartment were taken at the beginning and the end of the experiments.  The peptide 
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3.4.7 LC-ESI-MS/MS analysis  
Sample preparation for CJ-15,208 and [D-Trp]CJ-15,208   
The samples from the transport studies of CJ-15,208 and [D-Trp]CJ-15,208 were stored at 
0 oC immediately after the experiments. Following thawing, the internal standard cyclo[L-Phe-N-
Me-D-Ala-L-Phe-Trp] (20 L of a 12.5 M solution in MeCN) was added to 80 L of the transport 
samples. The samples were vortexed and stored in glass vials to prevent the hydrophobic 
macrocyclic peptides from absorbing onto the sides of plastic containers. 
LC-MS/MS method for CJ-15,208 and [D-Trp]CJ-15,208   
LC-MS/MS analysis was performed by Dr. Tanvir Khaliq and by staff from the University 
of Kansas Mass Spectroscopy Laboratory. Liquid chromatography was performed on a Hypersil 
BDS C8 column (3 μ, 2.1 mm × 50 mm). Sample injection volume was 20 μL, and analysis was 
conducted using a gradient on a Waters Acquity Classic UPLC (Waters Corp., Milford MA) at a 
flow rate of 0.27 mL/min. Peptides were separated using a gradient of water (solvent A) and 
acetonitrile (solvent B), both containing 0.08% formic acid, as follows: 0-2 min (20% B), 2-3 min 
(20-50% B), 3-6 min (50-80% B), 6-7 min (80% B), 7-8 min (80-20% B) and 8-10 min (20% B). 
The retention times for CJ-15,208 and [D-Trp]CJ-15,208 were 3.8 min and 6.4 min, respectively, 
and the retention time of the IS was 4.5 min. 
The UPLC was coupled to a triple quadrupole mass spectrometer (Quattro Ultima 
Micromass Ltd., Manchester UK) operating in the positive-ion mode. Cone voltage and collision 
induced dissociation conditions for precursor/product ion pairs of CJ-15,208 or [D-Trp]CJ-15,208 
and its internal standard were determined by post column mixing of standards infused under UPLC 
elution conditions. Data acquisition was carried out with Mass Lynx 4.1 software with the 
following settings: capillary voltage, 2.8 kV; cone voltages, 80 V IS, 30V analytes; source 
temperature, 100 °C; desolvation temperature, 220 °C; cone gas flow, 280 L/h; desolvation gas 
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flow, 1200 L/h. Q1 and Q3 resolution were 0.8 u FWHH. The argon filled collision cell pressure 
was 3.35 × 10-3 mbar on a gauge in-line with the cell. MRM was used for CJ-15,208 and [D-
Trp]CJ-15,208: [M + H]+ m/z 578.1 → 217.1 and 245.0, collision energy 30 eV and for the internal 
standard [M + H]+ m/z 566.2 → 232.9 (Figure 3.13), collision energy 22 eV, with a dwell time of 
0.3 s. The standard curve for the L-Trp isomer was obtained from 0.1 M to 25 M and displayed 
linearity (r2 = 0.9733, Figure 3.14). The standard curve for the D-Trp isomer was obtained from 
0.1 M to 25 M and displayed polynomial correlation (r2 = 0.9867, Figure 3.15). The transport 
samples were analyzed using the same conditions as the standards.  
 
 





Figure 3.14: Representative standard curve of CJ-15,208 by LC-MS/MS used for quantifying the 




Figure 3.15: Representative standard curve of [D-Trp]CJ15,208 by LC-MS/MS used for 
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3.4.8 Papp and percent permeability calculations 
The cumulative fraction of the drug transported at each time point was calculated by 
dividing the concentration in the receiver at each time point, following correction for aliquot 
removal (by addition of an equal volume of HBSS), by the donor concentration (concentration of 
the drug at time = 0). The cumulative fraction transported was plotted vs. time to obtain the slope 
of the line (flux). The Papp value was then calculated from the following formula: 
Papp = slope x volume of receiver chamber (cm
3)/area of the filter (cm2) x 60 (sec) 
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